Zacks Research Issues Positive Outlook for Cencora Earnings

Cencora, Inc. (NYSE:COR) – Equities research analysts at Zacks Research raised their Q3 2025 EPS estimates for Cencora in a report issued on Wednesday, February 26th. Zacks Research analyst I. Bandyopadhyay now expects that the company will earn $3.74 per share for the quarter, up from their prior forecast of $3.57. The consensus estimate for Cencora’s current full-year earnings is $15.37 per share. Zacks Research also issued estimates for Cencora’s Q1 2026 earnings at $3.93 EPS, Q2 2026 earnings at $4.45 EPS, FY2026 earnings at $16.65 EPS, Q1 2027 earnings at $4.21 EPS and FY2027 earnings at $18.07 EPS.

A number of other analysts also recently commented on COR. Wells Fargo & Company upped their target price on Cencora from $237.00 to $251.00 and gave the stock an “equal weight” rating in a research note on Wednesday, January 29th. Mizuho started coverage on shares of Cencora in a research note on Wednesday, December 4th. They set an “outperform” rating and a $280.00 target price for the company. Evercore ISI increased their price objective on Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a research note on Thursday, February 6th. Barclays increased their price objective on shares of Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Finally, UBS Group lifted their price target on Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, Cencora has an average rating of “Moderate Buy” and a consensus target price of $277.90.

Cencora Trading Down 0.8 %

NYSE COR opened at $248.71 on Friday. Cencora has a 1 year low of $214.77 and a 1 year high of $262.26. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. The company has a market capitalization of $48.23 billion, a PE ratio of 35.38, a P/E/G ratio of 1.31 and a beta of 0.49. The company has a fifty day moving average of $240.74 and a 200 day moving average of $237.66.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, topping analysts’ consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 3rd. Shareholders of record on Friday, February 14th will be given a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 0.88%. The ex-dividend date is Friday, February 14th. Cencora’s payout ratio is 31.29%.

Insider Activity at Cencora

In other Cencora news, EVP Silvana Battaglia sold 5,000 shares of the stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the sale, the executive vice president now directly owns 15,374 shares in the company, valued at $3,724,197.76. This represents a 24.54 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 10.80% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of COR. Whittier Trust Co. lifted its holdings in Cencora by 0.6% during the 4th quarter. Whittier Trust Co. now owns 7,856 shares of the company’s stock worth $1,765,000 after buying an additional 44 shares during the last quarter. Venturi Wealth Management LLC boosted its stake in Cencora by 1.0% during the 3rd quarter. Venturi Wealth Management LLC now owns 4,447 shares of the company’s stock worth $1,001,000 after purchasing an additional 46 shares during the period. Prime Capital Investment Advisors LLC grew its holdings in shares of Cencora by 1.2% during the third quarter. Prime Capital Investment Advisors LLC now owns 3,768 shares of the company’s stock worth $848,000 after buying an additional 46 shares during the last quarter. Shepherd Financial Partners LLC grew its stake in shares of Cencora by 0.9% in the 4th quarter. Shepherd Financial Partners LLC now owns 5,441 shares of the company’s stock valued at $1,223,000 after purchasing an additional 46 shares during the last quarter. Finally, WASHINGTON TRUST Co grew its position in Cencora by 37.7% in the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company’s stock valued at $38,000 after buying an additional 46 shares during the last quarter. 97.52% of the stock is owned by institutional investors and hedge funds.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.